You raise a very good counterpoint suggestion to my doom-and-gloom fear that they're going to announced a reverse split. The Investors Day event would make sense if they announce on earnings day at the end of the month that they are switching Vascepa to a generic in the U.S. I imagine they waited one quarter to see exactly how much their revenue dropped with the loss of that deal that brought us 25 percent of our revenues. If the loss on the quarter was substantial, it would make sense that they'd switch to a generic and say at earnings time that they're staging an Investor Day in a few weeks to better educate investors on what this will mean for Amarin going forward.
Actually, as I was writing the above, I was thinking that this is a more likely purpose for the Investor Day than my Doom and Gloom scenario.
Market Data 
Markets 
AI
